KRSA
Korsana Biosciences, Inc.
Healthcare — Biotechnology
Korsana Biosciences, Inc., a biotechnology company that discovers and develops novel therapies for neurodegenerative diseases. The company was incorporated in 2024 and is based in Waltham, Massachusetts.
Strong Buy
1.0 / 5
1 analysts
$31.20
$-0.80 (-2.50%)
Target:
$55.00
(76.3%)
Price History
52-Week Range
Sign in to add KRSA to a watchlist or set price alerts.
Fundamentals
| Market Cap | - |
| P/E Ratio (TTM) | - |
| Forward P/E | -18.56 |
| EPS (TTM) | - |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | Strong Buy 1.0 |
| Analyst Target | $55.00 |
| Analysts | 1 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 55.5 |
| Beta | - |
| SMA 20 | $28.48 |
| SMA 40 | $26.84 |
| 52-Week High | $59.36 |
| 52-Week Low | $7.19 |
| 50-Day Avg | $26.63 |
| 200-Day Avg | $18.29 |
| Avg Volume | 9.9K |
| Volume | 52.1K |
Performance Analysis
BULLISHKRSA shows predominantly bullish signals based on its fundamentals and technicals.
~
Trading at 46% of its 52-week range.
+
RSI at 55.5 shows positive momentum.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
+
Wall Street consensus is "Strong Buy" from 1 analysts.
+
Average analyst target of $55.00 implies 76.3% upside.
Recent News
Loading news...
Last updated: Sep 15, 2026 10:38 UTC
Back to Screener Export Report